Related Experiment Video
Updated: Jul 9, 2025
Growth, Purification, and Titration of Oncolytic Herpes Simplex Virus
Published on: May 13, 2021
Advances in oncolytic herpes simplex virus and adenovirus therapy for recurrent glioma
Mingming Hu1,2, XuLiang Liao1,2, Yi Tao1,2
1Institute of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.
Abstract:
Recurrent glioma treatment is challenging due to molecular heterogeneity and treatment resistance commonly observed in these tumors. Researchers are actively pursuing new therapeutic strategies. Oncolytic viruses have emerged as a promising option. Oncolytic viruses selectively replicate within tumor cells, destroying them and stimulating the immune system for an enhanced anticancer response. Among Oncolytic viruses investigated for recurrent gliomas, oncolytic herpes simplex virus and oncolytic adenovirus show notable potential. Genetic modifications play a crucial role in optimizing their therapeutic efficacy. Different generations of replicative conditioned oncolytic human adenovirus and oncolytic HSV have been developed, incorporating specific modifications to enhance tumor selectivity, replication efficiency, and immune activation. This review article summarizes these genetic modifications, offering insights into the underlying mechanisms of Oncolytic viruses' therapy. It also aims to identify strategies for further enhancing the therapeutic benefits of Oncolytic viruses. However, it is important to acknowledge that additional research and clinical trials are necessary to establish the safety, efficacy, and optimal utilization of Oncolytic viruses in treating recurrent glioblastoma.
Insights
Oncolytic viruses offer a promising new treatment for recurrent gliomas by selectively destroying tumor cells and boosting immune response. Genetic modifications enhance these oncolytic viruses, like oncolytic herpes simplex virus and adenovirus, for better efficacy.
Area of Science:
- * Oncology
- * Virology
- * Immunotherapy
Background:
- * Recurrent gliomas present significant treatment challenges due to molecular heterogeneity and resistance.
- * Oncolytic viruses are being explored as a novel therapeutic strategy for these difficult-to-treat tumors.
- * Existing treatments for recurrent glioma often have limited efficacy.
Purpose of the Study:
- * To review the genetic modifications of oncolytic viruses for treating recurrent gliomas.
- * To explore the mechanisms of action for oncolytic virus therapy.
- * To identify strategies for improving the therapeutic benefits of oncolytic viruses.
Main Methods:
- * Review of current literature on oncolytic virus therapy for recurrent gliomas.
- * Analysis of genetic modifications in oncolytic herpes simplex virus (HSV) and adenovirus.
- * Examination of mechanisms underlying tumor cell lysis and immune stimulation.
Main Results:
- * Oncolytic herpes simplex virus and oncolytic adenovirus show significant potential in preclinical studies.
- * Genetic engineering enhances tumor selectivity, replication, and immune activation of oncolytic viruses.
- * Different generations of modified oncolytic viruses have been developed.
Conclusions:
- * Genetically modified oncolytic viruses represent a promising avenue for recurrent glioma treatment.
- * Further research and clinical trials are essential to establish safety and efficacy.
- * Optimizing oncolytic virus strategies could improve outcomes for recurrent glioblastoma patients.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...